Phase 1/2a, dose-escalation, safety and proof of concept study of intravesical DTA-H19 [BC 819] in patients with superficial bladder cancer.
Phase of Trial: Phase I/II
Latest Information Update: 17 Jan 2019
At a glance
- Drugs Inodiftagene-vixteplasmid (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions; Proof of concept
- 31 Aug 2018 Biomarkers information updated
- 04 Jan 2008 Status changed from in progress to completed.
- 27 Jun 2007 Status changed from recruiting to in progress.